Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25615317 | 0.90 | GRM1 (0.33) | GRM1FFAR3 | |
| SCHEMBL3929521 | 0.83 | FFAR3 (0.35) | GRM1FFAR3 | |
| SCHEMBL17582307 | 0.80 | — | — | |
| SCHEMBL25745100 | 0.80 | — | — | |
| SCHEMBL478303 | 0.80 | GRM1 (0.40) | GRM1FFAR3 | |
| SCHEMBL960223 | 0.78 | GRM1 (0.41) | GRM1 | |
| SCHEMBL16933182 | 0.74 | GRM1 (0.40) | GRM1FFAR3 | |
| SCHEMBL16701062 | 0.73 | GRM1 (0.43) | GRM1 | |
| SCHEMBL893183 | 0.73 | FFAR3 (0.44) | GRM1FFAR3 | |
| SCHEMBL10151921 | 0.72 | GRM1 (0.36) | GRM1FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634159-A1 | SULFOXIMINES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2025-10-22 | — | — | EP | disclosed |
| US-20240252473-A1 | Sulfoximines as inhibitors of NaV1.8 | GRUENENTHAL GMBH (DE) | 2024-08-01 | — | — | US | disclosed |
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240208986-A1 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024126648-A1 | SULFOXIMINES AS INHIBITORS OF NaV1.8 | Grünenthal GmbH (DE) | 2024-06-20 | — | — | WO | disclosed |
| EP-4329766-A1 | RIPK1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4329765-A1 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022231927-A1 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2022-11-03 | — | — | WO | disclosed |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-05 | — | — | US | disclosed |
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| WO-2015073763-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015073763-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | GRM1 2287/4885FFAR3 3688/4885 |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | GRM1 1884/4885FFAR3 3720/4885 |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | GRM1 1884/4885FFAR3 3720/4885 |
| US-20240252473-A1 | Sulfoximines as inhibitors of NaV1.8 | SCN8A, SCN10A, SCN7A | GRM1 276/4885FFAR3 2590/4885 |
| US-20240208986-A1 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | RIPK1, RIPK2, RIPK4 | GRM1 1729/4885FFAR3 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.